)
Heron Therapeutics (HRTX) investor relations material
Heron Therapeutics Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Q2 2026 net revenue was $37.7 million, up 9% sequentially but flat year-over-year and slightly below expectations.
Acute care franchise revenue grew 43.9% year-over-year, driven by ZYNRELEF (up 35%) and APONVIE (up 74%), while oncology franchise revenue declined 15.9% year-over-year due to competition.
Net loss widened to $5.5 million in Q2 2026 from $2.4 million in Q2 2025.
SUSTOL continues its planned wind down and will be withdrawn from the market as of September 30, 2026.
Strategic alternatives are under review, with spending tightened and sales force expansion paused following recent legal developments.
Financial highlights
Gross margin for Q2 2026 was 69.3%, down from 73.5% in Q2 2025.
R&D expense was $2.7 million; SG&A expense was $25.4 million; total operating expenses were $28.1 million.
Adjusted EBITDA was $3.2 million, up from $2.2 million year-over-year.
Cash and short-term investments at quarter-end were $42.7 million.
Cost of product sales rose 17.4% in Q2, reflecting higher inventory reserves and increased units sold.
Outlook and guidance
Full-year 2026 guidance for net product sales and adjusted EBITDA was withdrawn due to uncertainty from a June court decision and potential generic competition.
Management expects cash resources to cover at least one year of operations, but this is based on assumptions that could change.
Will report cash position, spending, and covenant compliance quarterly instead of annual guidance.
Strategic alternatives are being considered, with no assurance of a transaction or favorable terms.
- All director nominees and proposals were approved, with no questions from stockholders.HRTX
AGM 2026 - Q1 2026 net sales $34.7M; Acute Care up, Oncology down; guidance reaffirmed.HRTX
Q1 2026 - Shareholders will vote on directors, compensation, equity plans, and tax benefit protections.HRTX
Proxy filing - Key votes include director elections, plan amendments, and auditor ratification for 2026.HRTX
Proxy filing - Shareholders will vote on directors, auditor, compensation, equity plans, and tax benefit protections.HRTX
Proxy filing - 2025 net revenue rose 7.4% to $154.9M, driven by Acute Care growth and new CMS J-Codes.HRTX
Q4 2025 - Q3 2024 featured higher sales, margin gains, and catalysts for future product expansion.HRTX
Q3 2024 - Q2 2024 sales rose to $36M, margin improved, and ZYNRELEF set for growth with VAN and NOPAIN Act.HRTX
Q2 2024 - Achieved full-year profitability and 14% revenue growth, led by ZYNRELEF and APONVIE momentum.HRTX
Q4 2024
Next Heron Therapeutics earnings date
Next Heron Therapeutics earnings date
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
)
)